Shoulder Arthroplasty Clinical Trial
Official title:
Single Injection Interscalene Brachial Plexus Nerve Block With Adjuvants vs. Liposomal Bupivacaine Interscalene Brachial Plexus Nerve Block for Total Shoulder Arthroplasty
Verified date | September 2022 |
Source | Wake Forest University Health Sciences |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
The purpose of this study is to determine whether the use of plain bupivacaine with common adjuvants for interscalene block (ISB) provides non-inferior analgesic results compared to the use of liposomal bupivacaine for ISB, in patients undergoing total shoulder arthroplasty.
Status | Terminated |
Enrollment | 25 |
Est. completion date | June 25, 2022 |
Est. primary completion date | June 25, 2022 |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | All |
Age group | 18 Years and older |
Eligibility | Inclusion Criteria: - All patients undergoing total shoulder arthroplasty (not a reverse) - Age = 18 years - Ability to understand and the willingness to sign an IRB-approved informed consent document. - ASA patient status I-III patients - Weight Greater than or equal to 50 kg Exclusion Criteria: - Contraindications to an interscalene block or phrenic blockade - Infection at injection site - Pre-existing neurological dysfunction affecting the operative extremity - Chronic pain diagnosis or opioid use >40mg oxycodone daily equivalents or use of long-acting opioids - BMI >40 - Uncontrolled diabetes (A1c >8.0) - Concurrent painful physical condition requiring analgesic treatment (eg, NSAID or opioid) in the postsurgical period for pain not strictly related to the surgery - Contraindications to any pain-control agents planned for surgical or postsurgical use (i.e., bupivacaine, hydromorphone, etc.) - Patients who are wards of the state - History of allergic reactions attributed to compounds of similar chemical or biologic composition to bupivacaine or liposomal bupivacaine. - Patients with moderate-severe hepatic or renal impairment |
Country | Name | City | State |
---|---|---|---|
United States | Wake Forest University Health Sciences | Winston-Salem | North Carolina |
Lead Sponsor | Collaborator |
---|---|
Wake Forest University Health Sciences |
United States,
Hamilton TW, Athanassoglou V, Mellon S, Strickland LH, Trivella M, Murray D, Pandit HG. Liposomal bupivacaine infiltration at the surgical site for the management of postoperative pain. Cochrane Database Syst Rev. 2017 Feb 1;2(2):CD011419. doi: 10.1002/14651858.CD011419.pub2. — View Citation
Hamilton TW, Athanassoglou V, Trivella M, Strickland LH, Mellon S, Murray D, Pandit HG. Liposomal bupivacaine peripheral nerve block for the management of postoperative pain. Cochrane Database Syst Rev. 2016 Aug 25;2016(8):CD011476. doi: 10.1002/14651858.CD011476.pub2. — View Citation
Pichler L, Poeran J, Zubizarreta N, Cozowicz C, Sun EC, Mazumdar M, Memtsoudis SG. Liposomal Bupivacaine Does Not Reduce Inpatient Opioid Prescription or Related Complications after Knee Arthroplasty: A Database Analysis. Anesthesiology. 2018 Oct;129(4):689-699. doi: 10.1097/ALN.0000000000002267. — View Citation
Rabin T. FDA In Brief: FDA approves new use of Exparel for nerve block pain relief following shoulder surgeries.
Sakamoto B, Keiser S, Meldrum R, Harker G, Freese A. Efficacy of Liposomal Bupivacaine Infiltration on the Management of Total Knee Arthroplasty. JAMA Surg. 2017 Jan 1;152(1):90-95. doi: 10.1001/jamasurg.2016.3474. — View Citation
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Average Pain Scores for the First 48 Hours | Pain levels will be measured by the mean Visual Analogue Scale- Numeric Rating Scale (VAS-NRS). The VAS-NRS is an 11 point scale with 0 (no pain) to 10 (worst possible pain). Higher scores denote worse outcome. | At 48 hours postoperatively | |
Secondary | Postoperative Opioid Consumption for the First 48 Hours | Morphine milligram equivalents (MME) over a 48 hour period | up to 48 hours | |
Secondary | Satisfaction With Surgical Experience | Satisfaction scale is from 1-5, with the higher score being highest level of satisfaction | at 48 hours |
Status | Clinical Trial | Phase | |
---|---|---|---|
Not yet recruiting |
NCT05965986 -
Preoperative Rehabilitation and Education Program
|
N/A | |
Completed |
NCT05020821 -
Superior Trunk Block Catheter Versus Single-shot Superior Trunk Block With Intravenous Dexmedetomidine for Shoulder Arthroplasty
|
N/A | |
Completed |
NCT05350319 -
Prospective Low Dose CT for Total Shoulder Arthroplasty/Reverse Shoulder Arthroplasty
|
||
Recruiting |
NCT05699031 -
Shoulder Prosthesis Telerehab Care Trial
|
N/A | |
Completed |
NCT04822610 -
Comparison of Interscalene Block and Suprascapular With Axillary Block
|
N/A | |
Terminated |
NCT03858517 -
A Post-Market Clinical Evaluation of the ReUnion TSA System
|
||
Terminated |
NCT03880955 -
A Post-Market Clinical Evaluation of the ReUnion Reverse Shoulder Arthroplasty (RSA) System
|
||
Recruiting |
NCT03511586 -
Total Shoulder Arthroplasty Multi-Center Registry
|
||
Completed |
NCT04112407 -
The Effect of Pretreatment for Propionibacterium Acnes on Surgical Site Burden in Shoulder Arthroplasty
|
N/A | |
Recruiting |
NCT03268837 -
Programmed Intermittent Bolus During Continuous Interscalene Nerve Block for Shoulder Arthroplasty
|
N/A | |
Active, not recruiting |
NCT06281574 -
What Are the Determinants for RTW After SA
|
||
Completed |
NCT05179941 -
Subscapularis Indocyanine Green Perfusion Pilot Study
|
N/A | |
Completed |
NCT03578237 -
Cryoanalgesia to Prevent Acute and Chronic Pain Following Surgery: A Randomized, Double-Masked, Sham-Controlled Study
|
N/A | |
Recruiting |
NCT00527839 -
Hospital for Special Surgery Shoulder Arthroplasty Cohort
|